HAE vs GMED
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
HAE · Haemonetics$120.16 ▼ 0.17%
GMED · Globus Medical$66.89 ▼ 2.49%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- HAE +50.9%
- GMED -23.9%
Head to head
| Metric | HAE | GMED |
|---|---|---|
| Price | $120.16 | $66.89 |
| Change today | ▼ 0.17% | ▼ 2.49% |
| Market cap | $5.47B | $8.86B |
| Return, 3 months | +10.8% | -20.4% |
| Return, year to date | +49.9% | -23.4% |
| Return, 1 year | +52.5% | -22.2% |
| P/E (TTM) | 53.2 | 16.5 |
| P/B | 6.1 | 1.8 |
| P/E percentile vs own 5y | 78th | 1st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +9.3% | -0.7% |
| Net profit growth (YoY) | +19.7% | +18.7% |
| Gross margin | 59.6% | 69.1% |
| Operating margin | 18.3% | 22.8% |
| Net margin | 7.5% | 17.8% |
| Return on equity | 11.9% | 12.1% |
| Analyst target vs. price | +21.3% | +39.4% |
| Analyst buy share | 80% | 70% |
| RSI (14) | 52 | 35 |
| 30-day volatility | 30.2% | 66.2% |
| Max drawdown, 1 year | -40.1% | -30.9% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GMED is the largest of the group by market value.
- HAE has returned the most over the past year.
- GMED carries the lowest trailing P/E.
- HAE is growing revenue fastest.
- GMED keeps the most profit per dollar of sales.
- HAE has been the calmest stock over the last 30 days.